Early-Stage Biopharma Investment Strategies

When it comes to mergers, acquisitions, and licensing strategy in biopharma, ¬†every company has a unique, individual strategy based on their respective resources, assets, and strategic plan. It’s important for each company to repeatedly internally assess their potential strategies, and make decisions from there about how to proceed or what changes to make. These analyses […]

Baxter Sets up $200M Venture Arm for Early-Stage Investments

By John Carroll Baxter International is setting up its own corporate venture unit with plans to inject up to $200 million to be invested in early-stage companies with promising new technologies. “Baxter’s mission is to apply innovative science to develop therapies and medical technologies that save and sustain patients’ lives,” said Baxter CEO Robert L. […]

PwC Tracks a Spike in VC Cash and Deals for Biotechs

By John Carroll PricewaterhouseCoopers and the National Venture Capital Association crunched the numbers on venture investing in the second quarter, tracking a 46% spike in the amount of venture cash being injected into U.S. biotech companies. Biotechs garnered $1.2 billion in venture funds for the quarter, with deal activity jumping 20%–from 97 rounds in the […]

DVS Sciences Lands $14.6M Round with Big Pharma Support

By Ryan McBride Big names in life sciences are backing DVS Sciences in a $14.6 million Series A round. With biomarker analysis technology for personalized medicine, the start-up has garnered investments from the investment vehicles of drug giants Pfizer ($PFE) and Roche as well as the venture firms 5AM Ventures and Mohr Davidow Ventures. 5AM […]

KPMG: Expect More Pharma M&A

By Tracy Staton If you’re a pharma M&A junkie, then the next couple of years should make you happy. Unfortunately, the news isn’t as good for those seeking a job in the drug industry. That’s the message from a new KPMG survey of 100 pharma executives, many of whom expect difficult times ahead. Some 83% […]

Zafgen Banks $33M C Round as it Preps for Ph2 Obesity Study

By John Carroll Cambridge-based upstart Zafgen has rounded up $33 million in a third venture round as it sets out to prove in an upcoming mid-stage trial that it has a viable therapeutic alternative to bariatric surgery. Encouraged by signs of dramatic weight loss in Phase I, Zafgen’s two venture backers–Atlas Venture and Third Rock–are […]

AZ Financial Backing to Fuel PTC Oncology Cures

By George Miller AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC’s proprietary discovery/development technology platform. AZ will front an undisclosed amount of cash to start work on the first oncology target. The drug giant has also agreed to “committed research funding,” according to an announcement. The platform, called Gene Expression Modulation […]

Novartis Venture Fund Leads $36M Raise for Sorbent

By John Carroll Novartis Venture Fund has stepped in to lead a big Series B expansion for Sunnyvale, CA-based Sorbent Therapeutics, which is engaged in a mid-stage trial of a new treatment designed to flush excess amounts of fluids like sodium and potassium from patients. Novartis joined Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and […]

Tesaro Lands $101M B Round as it Preps for New Cancer Drug Acquisitions

By John Carroll The veteran crew of cancer drug developers at MGI Pharma who went on to found†Tesaro a little more than a year ago have rounded up a whopping $101 million B round led by Kleiner Perkins Caufield & Byers. The cash gives the Boston-based biotech more cash to follow up on its late-stage […]

Pfizer Unveils $100M Boston Effort to Spark R&D Innovation

By John Carroll Pfizer’s quest to find a more productive way to discover and advance important new treatments is taking the pharma giant on a journey back to college in Boston. With some of Pfizer’s R&D luminaries joining hands with top politicians, the company announced a $100 million, five-year plan to establish a new Center […]